Professur für Translationale Frauenheilkunde und Geburtshilfe

Clinical validation of genetic variants associated with in vitro chemotherapy-related lymphoblastoid cell toxicity (2017) Fasching P, Häberle L, Rack B, Li L, Hein A, Ekici AB, Reis A, et al. Journal article Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients (2017) Banys-Paluchowski M, Witzel I, Riethdorf S, Rack B, Janni W, Fasching P, Solomayer EF, et al. Journal article Biological and clinical effects of abemaciclib in a phase 2 neoadjuvant study for postmenopausal patients with HR+/HER2-breast cancer (2017) Guarneri V, Fasching P, Fernandez Abad M, Garcia-Saenz A, Schneeweiss A, Colleoni M, Petru E, et al. Conference contribution Biological and clinical effects of abemaciclib in a phase 2 neoadjuvant study for postmenopausal patients with HR+/HER2-breast cancer (2017) Fasching P, Fernandez Abad M, Garcia-Saenz JA, Schneeweiss A, Guarneri V, Colleoni M, Petru E, et al. Conference contribution Circulating Tumour Cells, Circulating Tumour DNA and Circulating MicroRNA in Metastatic Breast Carcinoma - What is the Role of Liquid Biopsy in Breast Cancer? (2017) Polasik A, Tzschaschel M, Schochter F, De Gregorio A, Friedl TWP, Rack B, Hartkopf A, et al. Journal article BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer (2017) Shimelis H, Mesman RLS, Von Nicolai C, Ehlen A, Guidugli L, Martin C, Calleja FMGR, et al. Journal article Anti-Müllerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy - A translational research project of the SUCCESS A study (2017) Trapp E, Steidl J, Rack B, Kupka MS, Andergassen U, Jueckstock J, Kurt A, et al. Journal article Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci (2017) Glubb DM, Johnatty SE, Quinn MCJ, O'Mara TA, Tyrer JP, Gao B, Fasching P, et al. Journal article Updates on the role of receptor activator of nuclear factor κB/receptor activator of nuclear factor κB ligand/osteoprotegerin pathway in breast cancer risk and treatment (2017) Bayer CM, Beckmann M, Fasching P Journal article TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer (2017) Fagerholm R, Khan S, Schmidt MK, Garcia-Closas M, Heikkila P, Saarela J, Beesley J, et al. Journal article